Research Reports

Key takeaways

Jeff Knight appointed Chief Development and Operating Officer effective April 13, 2026.

Base salary $565,000; target cash bonus 40% of base.

Granted stock option for 800,000 shares under 2025 Inducement Equity Incentive Plan, vesting 25% after one year then monthly.

Over 30 years biopharma experience, most recently CDOO at Crinetics Pharmaceuticals from September 2021 to April 2026.

No arrangements or family relationships influencing appointment.

Entered standard change of control, severance, and indemnification agreements.

Full analysis

The appointment of Jeff Knight as Chief Development and Operating Officer brings extensive experience in clinical development, operations, and portfolio management from prior roles at Crinetics, Poseida, Halozyme, Amgen, Onyx, and Genentech. This leadership addition is positioned to support ALX Oncology's upcoming catalysts in evorpacept and ALX2004 programs over the next 12-18 months, enhancing development capabilities and operational execution. Compensation includes competitive base pay, performance-based bonus, and significant equity incentive aligned with long-term service, with standard protections via severance and indemnification agreements.

ALXO · ALX Oncology Holdings Inc.

Summary

Key takeaways

Full analysis